admin's picture

SUVA, Fiji (Fiji TV, Nov. 29) – A major pharmaceutical breakthrough has been announced in Fiji with the approval of Risperidone, a drug developed in Fiji to be marketed in the Netherlands and New Zealand.

While the drug doesn't go on sale until 2007, developer Douglas Pharmaceuticals Fiji says six years of hard work have paid off handsomely.

Risperidone, which is an anti-psychotic drug, has taken 6 years to be developed at the Dougals Pharmaceutical Center in Nadi.

This achievement comes at a cost of around FJ$1.5 million (US$865,000).

Douglas Pharmaceuticals Fiji is a drug product development facility whose main market is Europe.

Two countries have already given their authorization to market the new product; officials say they are optimistic other countries will follow.

The drug is for patients with mental disorder and will come in six different dosages.

November 30, 2005

Fiji TV:

Rate this article: 
No votes yet

Add new comment